Protalix BioTherapeutics, Inc. (PLX)

Commercial-stage biotech with strong liquidity and partner-backed product revenue. Recent profitability improved sharply but is materially boosted by a disclosed one-time milestone, while the cash-flow track record remains choppy and a discounted-cash-flow model outputs negative values. Overall, this is a mixed setup: healthier balance sheet and momentum, but sustainability of earnings and cash generation is still the key open question.

Dominant catalyst is the 2026-08-12 Q2 2026 earnings print — an EPS beat the tape rewarded with a ≈6.6% rally, regulator_confirmed via the same-day 8-K — read bullish on market reception and partially priced. Sentiment delta is determinate at item level with moderate confidence (stable-to-improving vs a mildly positive +0.07 baseline); the Red-Flag Screen is clean with no cap applied, but the catalyst is trailing with no forward-dated event, leaving a forming rather than actionable setup.

Strong bullish trend structure: price 2.67 trades above SMA20 (2.47), SMA50 (2.40) and SMA200 (2.24), with EMA9 (2.57) and EMA21 (2.49) stacked below price. MACD line 0.07 is above signal 0.05 and above zero with an expanding positive histogram (0.02); RSI14 65.68 is firm but not extreme; ADX14 55.62 with price above all key moving averages confirms a strong established UPTREND. One weak signal: Williams %R at -2.50 sits near overbought. Technical score 4 (strong setup, one weak signal). The trade is nevertheless suppressed: the 20-day average dollar volume of ~$2.03M is far below the $5M liquidity floor, a hard block that no chart quality can override.